Carl Hull Acquires 175,000 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stock

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) insider Carl Hull acquired 175,000 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was purchased at an average cost of $5.64 per share, with a total value of $987,000.00. Following the acquisition, the insider now directly owns 175,000 shares of the company’s stock, valued at $987,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Maravai LifeSciences Stock Performance

Shares of Maravai LifeSciences stock opened at $5.63 on Thursday. The company has a debt-to-equity ratio of 0.71, a current ratio of 10.00 and a quick ratio of 9.28. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of -3.43 and a beta of 0.02. The business has a 50-day moving average of $7.97 and a 200 day moving average of $8.48. Maravai LifeSciences Holdings, Inc. has a 12 month low of $4.68 and a 12 month high of $11.56.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. William Blair reissued a “market perform” rating on shares of Maravai LifeSciences in a research note on Friday, November 8th. Morgan Stanley cut Maravai LifeSciences from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $11.00 to $10.00 in a research note on Tuesday, August 13th. UBS Group upped their price target on Maravai LifeSciences from $8.50 to $11.00 and gave the company a “neutral” rating in a research note on Thursday, August 8th. The Goldman Sachs Group cut their price objective on Maravai LifeSciences from $8.00 to $7.00 and set a “neutral” rating for the company in a research report on Tuesday, October 8th. Finally, Royal Bank of Canada decreased their target price on shares of Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Maravai LifeSciences presently has a consensus rating of “Moderate Buy” and an average target price of $10.33.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Quent Capital LLC boosted its position in Maravai LifeSciences by 26,315.8% in the 1st quarter. Quent Capital LLC now owns 15,057 shares of the company’s stock valued at $131,000 after buying an additional 15,000 shares during the period. Headlands Technologies LLC purchased a new position in Maravai LifeSciences in the first quarter valued at $42,000. QRG Capital Management Inc. grew its stake in Maravai LifeSciences by 11.7% during the 1st quarter. QRG Capital Management Inc. now owns 17,143 shares of the company’s stock worth $149,000 after purchasing an additional 1,796 shares in the last quarter. Bleakley Financial Group LLC increased its holdings in Maravai LifeSciences by 24.6% during the 1st quarter. Bleakley Financial Group LLC now owns 29,613 shares of the company’s stock worth $257,000 after purchasing an additional 5,853 shares during the period. Finally, Orion Portfolio Solutions LLC raised its position in Maravai LifeSciences by 14.4% in the 1st quarter. Orion Portfolio Solutions LLC now owns 115,239 shares of the company’s stock valued at $999,000 after purchasing an additional 14,519 shares in the last quarter. Hedge funds and other institutional investors own 50.25% of the company’s stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.